Moreover, the 36-month beta value for RNA is 0.94. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNA is 109.84M and currently, short sellers hold a 14.37% of that float. On June 05, 2025, RNA’s average trading volume was 1.48M shares.
RNA) stock’s latest price update
The stock of Avidity Biosciences Inc (NASDAQ: RNA) has decreased by -0.55 when compared to last closing price of 34.41.Despite this, the company has seen a gain of 10.74% in its stock price over the last five trading days. prnewswire.com reported 2025-05-21 that SAN DIEGO , May 21, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2025, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 71,000 shares of its common stock and 35,000 restricted stock units (“RSUs”) to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the “2022 Inducement Plan”). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
RNA’s Market Performance
Avidity Biosciences Inc (RNA) has seen a 10.74% rise in stock performance for the week, with a 6.01% gain in the past month and a 15.80% surge in the past quarter. The volatility ratio for the week is 4.13%, and the volatility levels for the past 30 days are at 3.61% for RNA. . The simple moving average for the past 20 days is 12.33% for RNA’s stock, with a -4.95% simple moving average for the past 200 days.
Analysts’ Opinion of RNA
Many brokerage firms have already submitted their reports for RNA stocks, with Citigroup repeating the rating for RNA by listing it as a “Buy.” The predicted price for RNA in the upcoming period, according to Citigroup is $70 based on the research report published on March 13, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see RNA reach a price target of $72. The rating they have provided for RNA stocks is “Outperform” according to the report published on March 12th, 2025.
Scotiabank gave a rating of “Sector Outperform” to RNA, setting the target price at $70 in the report published on March 07th of the current year.
RNA Trading at 15.75% from the 50-Day Moving Average
After a stumble in the market that brought RNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.89% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNA starting from Gallagher Kathleen P., who sale 5,875 shares at the price of $32.48 back on Jun 02 ’25. After this action, Gallagher Kathleen P. now owns 50,554 shares of Avidity Biosciences Inc, valued at $190,833 using the latest closing price.
KATHLEEN GALLAGHER, the Officer of Avidity Biosciences Inc, proposed sale 5,875 shares at $30.98 during a trade that took place back on Jun 02 ’25, which means that KATHLEEN GALLAGHER is holding shares at $182,008 based on the most recent closing price.
Stock Fundamentals for RNA
Current profitability levels for the company are sitting at:
- -48.53 for the present operating margin
- 0.92 for the gross margin
The net margin for Avidity Biosciences Inc stands at -41.36. The total capital return value is set at -0.32. Equity return is now at value -34.19, with -30.63 for asset returns.
Based on Avidity Biosciences Inc (RNA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -59.48.
Currently, EBITDA for the company is -376.16 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 434.25. The receivables turnover for the company is 0.24for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.91.
Conclusion
To wrap up, the performance of Avidity Biosciences Inc (RNA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
